Liisa Bayko
Stock Analyst at Evercore ISI Group
(3.68)
# 760
Out of 5,152 analysts
81
Total ratings
59.7%
Success rate
26.48%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Liisa Bayko
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RARE Ultragenyx Pharmaceutical | Maintains: Outperform | $37 → $34 | $21.46 | +58.43% | 10 | Feb 18, 2026 | |
| CRSP CRISPR Therapeutics AG | Maintains: Outperform | $62 → $74 | $57.33 | +29.08% | 3 | Feb 13, 2026 | |
| VRTX Vertex Pharmaceuticals | Maintains: Outperform | $475 → $530 | $460.82 | +15.01% | 20 | Jan 23, 2026 | |
| ENTA Enanta Pharmaceuticals | Maintains: Outperform | $20 → $12 | $13.74 | -12.66% | 5 | Sep 15, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | $280 → $515 | $320.51 | +60.70% | 2 | Sep 11, 2025 | |
| SVRA Savara | Maintains: In-Line | $3 → $2 | $5.49 | -63.57% | 5 | May 28, 2025 | |
| TVTX Travere Therapeutics | Maintains: Outperform | $33 → $45 | $27.31 | +64.77% | 5 | Feb 12, 2025 | |
| BCRX BioCryst Pharmaceuticals | Maintains: Outperform | $10 → $12 | $8.50 | +41.18% | 5 | Jan 13, 2025 | |
| EDIT Editas Medicine | Maintains: Outperform | $7 → $5 | $1.90 | +163.85% | 5 | Dec 16, 2024 | |
| KNSA Kiniksa Pharmaceuticals International, | Maintains: Outperform | $30 → $35 | $46.02 | -23.95% | 4 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $405 → $360 | $439.34 | -18.06% | 9 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $7 → $2 | $1.71 | +16.96% | 3 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $25 | $3.51 | +613.27% | 1 | Jan 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $35 | $5.70 | +514.04% | 1 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $24 | $38.85 | -38.22% | 1 | Jun 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $30 | $13.58 | +120.91% | 1 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Outperform | $10 | $4.70 | +112.77% | 1 | Feb 5, 2020 |
Ultragenyx Pharmaceutical
Feb 18, 2026
Maintains: Outperform
Price Target: $37 → $34
Current: $21.46
Upside: +58.43%
CRISPR Therapeutics AG
Feb 13, 2026
Maintains: Outperform
Price Target: $62 → $74
Current: $57.33
Upside: +29.08%
Vertex Pharmaceuticals
Jan 23, 2026
Maintains: Outperform
Price Target: $475 → $530
Current: $460.82
Upside: +15.01%
Enanta Pharmaceuticals
Sep 15, 2025
Maintains: Outperform
Price Target: $20 → $12
Current: $13.74
Upside: -12.66%
Alnylam Pharmaceuticals
Sep 11, 2025
Maintains: Outperform
Price Target: $280 → $515
Current: $320.51
Upside: +60.70%
Savara
May 28, 2025
Maintains: In-Line
Price Target: $3 → $2
Current: $5.49
Upside: -63.57%
Travere Therapeutics
Feb 12, 2025
Maintains: Outperform
Price Target: $33 → $45
Current: $27.31
Upside: +64.77%
BioCryst Pharmaceuticals
Jan 13, 2025
Maintains: Outperform
Price Target: $10 → $12
Current: $8.50
Upside: +41.18%
Editas Medicine
Dec 16, 2024
Maintains: Outperform
Price Target: $7 → $5
Current: $1.90
Upside: +163.85%
Kiniksa Pharmaceuticals International,
Oct 30, 2024
Maintains: Outperform
Price Target: $30 → $35
Current: $46.02
Upside: -23.95%
Aug 8, 2024
Maintains: Outperform
Price Target: $405 → $360
Current: $439.34
Upside: -18.06%
May 16, 2024
Maintains: In-Line
Price Target: $7 → $2
Current: $1.71
Upside: +16.96%
Jan 18, 2023
Maintains: Outperform
Price Target: $14 → $25
Current: $3.51
Upside: +613.27%
Nov 23, 2021
Initiates: Outperform
Price Target: $35
Current: $5.70
Upside: +514.04%
Jun 8, 2021
Initiates: Outperform
Price Target: $24
Current: $38.85
Upside: -38.22%
Nov 24, 2020
Reinstates: Outperform
Price Target: $30
Current: $13.58
Upside: +120.91%
Feb 5, 2020
Upgrades: Market Outperform
Price Target: $10
Current: $4.70
Upside: +112.77%